Long-Term Results of Monoclonal Anti-Il2-Receptor Antibody Versus Polyclonal Antilymphocyte Antibodies as Induction Therapy in Renal Transplantation
A. Al Najjar(Centre Hospitalier Universitaire de Tours), Y Lebranchu(Centre Hospitalier Universitaire de Tours), Christiane Mousson(Metabolism and Renal Physiology), Isabelle Étienne(Université Libre de Bruxelles), Sophie Caillard(Hôpitaux Universitaires de Strasbourg), P. Le Pogamp(Centre Hospitalier Universitaire de Rennes), Frank Bridoux(Université de Poitiers), Yannick Le Meur(Université de Bretagne Occidentale), Bruno Hurault de Ligny(Hôpital Georges-Clemenceau), J. Marlière(Centre Hospitalier Universitaire de Tours), Olivier Toupance(Centre Hospitalier Universitaire de Reims)
Cited by 27
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
|Blood|2012|543
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520